Targeted Exosome For Drug Delivery

ShineOn's platform technology ”Targeted exosome for drug delivery”integrates advantage of nanobody based antibody and exosome techniques. Using genetically engineered parental cells, exosome surfaces was modified by introducing desired antibody gene sequences, enabling the secretion of exosomes carrying tumor-targeting antibodies. These exosomes exhibit specificity towards tumor cells and allow for the selective loading of drugs tailored to tumor characteristics, thereby minimizing damage to normal cells. This precise and efficient approach achieves effective tumor treatment with minimal exosome-based drugs.
SOB100 is the first proprietary platform “HLA-G targeted exosome” successfully developed by ShineOn, poised for scalable industrial production in novel drug development. The design of SOB100 received positive feedback from FDA. HLA-G serves not only as an immune checkpoint but also as a neo tumor target, highly overexpressed on various tumor cells. Exosomes engineered with HLA-G-specific nanoantibodies precisely navigate exosome to tumor cells expressing HLA-G.

Among the 3 exosomal pipeline products under development by ShineOn, SOB101 and SOB102 are SOB100-derived exosomal drugs.